GSK Return on Tangible Equity 2010-2022 | GSK
Current and historical return on tangible equity values for GSK (GSK) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| GSK Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2022-12-31 |
$18.50B |
$-13.94B |
-152.10% |
| 2022-09-30 |
$16.61B |
$-16.57B |
-108.49% |
| 2022-06-30 |
$6.07B |
$6.73B |
-34.22% |
| 2022-03-31 |
$6.97B |
$-24.88B |
-27.03% |
| 2021-12-31 |
$6.03B |
$-26.52B |
-23.14% |
| 2021-09-30 |
$6.00B |
$-26.30B |
-23.33% |
| 2021-06-30 |
$6.00B |
$-25.43B |
-23.15% |
| 2021-03-31 |
$6.86B |
$-25.99B |
-25.96% |
| 2020-12-31 |
$7.38B |
$-25.18B |
-27.28% |
| 2020-09-30 |
$8.12B |
$-27.03B |
-28.83% |
| 2020-06-30 |
$8.42B |
$-27.45B |
-28.81% |
| 2020-03-31 |
$6.86B |
$-28.57B |
-22.73% |
| 2019-12-31 |
$5.93B |
$-29.57B |
-19.35% |
| 2019-09-30 |
$5.56B |
$-31.37B |
-18.71% |
| 2019-06-30 |
$5.49B |
$-31.11B |
-19.49% |
| 2019-03-31 |
$4.85B |
$-30.55B |
-17.83% |
| 2018-12-31 |
$4.84B |
$-25.79B |
-18.39% |
| 2018-09-30 |
$2.83B |
$-25.26B |
-10.80% |
| 2018-06-30 |
$2.57B |
$-27.29B |
-9.86% |
| 2018-03-31 |
$1.74B |
$-26.86B |
-6.80% |
| 2017-12-31 |
$1.98B |
$-25.53B |
-7.95% |
| 2017-09-30 |
$3.71B |
$-24.69B |
-14.78% |
| 2017-06-30 |
$1.50B |
$-25.46B |
-5.76% |
| 2017-03-31 |
$2.14B |
$-23.68B |
-8.34% |
| 2016-09-30 |
$0.30B |
$-26.71B |
-1.22% |
| 2016-06-30 |
$0.07B |
$-28.47B |
-0.32% |
| 2016-03-31 |
$0.93B |
$-23.63B |
-4.63% |
| 2015-12-31 |
$12.77B |
$-19.81B |
-70.20% |
| 2015-09-30 |
$14.87B |
$-19.38B |
-91.97% |
| 2015-06-30 |
$14.68B |
$-17.05B |
-105.06% |
| 2015-03-31 |
$15.57B |
$-16.51B |
-130.64% |
| 2014-12-31 |
$4.44B |
$-11.72B |
-43.61% |
| 2014-09-30 |
$6.81B |
$-10.62B |
-71.86% |
| 2014-06-30 |
$7.73B |
$-8.82B |
-79.81% |
| 2014-03-31 |
$8.22B |
$-9.58B |
-79.35% |
| 2013-12-31 |
$8.56B |
$-8.88B |
-79.32% |
| 2013-09-30 |
$6.01B |
$-11.44B |
-51.55% |
| 2013-06-30 |
$6.25B |
$-11.53B |
-55.67% |
| 2013-03-31 |
$6.62B |
$-11.33B |
-67.82% |
| 2012-12-31 |
$7.30B |
$-12.32B |
-96.02% |
| 2012-09-30 |
$7.90B |
$-9.72B |
-140.71% |
| 2012-06-30 |
$8.28B |
$-5.70B |
-182.56% |
| 2012-03-31 |
$8.10B |
$-2.65B |
-190.23% |
| 2011-12-31 |
$8.41B |
$-4.38B |
-184.38% |
| 2011-09-30 |
$5.32B |
$-5.42B |
-121.83% |
| 2011-06-30 |
$5.21B |
$-4.59B |
-149.21% |
| 2011-03-31 |
$2.98B |
$-3.85B |
-92.26% |
| 2010-12-31 |
$2.60B |
$-3.60B |
-105.17% |
| 2010-09-30 |
$6.44B |
$-1.92B |
-296.65% |
| 2010-06-30 |
$6.60B |
$-3.55B |
-298.55% |
| 2010-03-31 |
$9.29B |
$-0.80B |
-684.44% |
| 2009-12-31 |
$8.92B |
$-2.41B |
-715.87% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$75.923B |
$36.279B |
|
GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.
|
